NeuroHeal Biomedicals: a new technology-based company of the UAB to develop a new treatment for peripheral nerve damage
- NeuroHeal Biomedicals: a new technology-based company of the UAB to develop a new treatment for peripheral nerve damage
- NeuroHeal Biomedicals will advance the development of a new drug to restore peripheral nerve well function. The objective of the company is to initiate clinical trials in humans within two years
The research team led by Dr. Caty Casas, from the Institute of Neurosciences of the Universitat Autònoma de Barcelona (INc-UAB), has created the company NeuroHeal Biomedicals to develop a new neuroprotective treatment that also accelerates the regeneration of damaged peripheral nerves.
The research team has already patented the new drug. Now the company’s aspiration is to complete the regulatory preclinical phase and move forward to conduct clinical studies in humans. “The development of a medicine is a long road, but we hope to start phase I trials in 2022 and move forward with this new therapy,” says Caty Casas.
In addition, this was the first project funded by the new GENESIS Ventures fund, and according to José Luis Falcó, CEO of this company “we are very happy to have invested in this promising project, even before it became a biotech-based company . Now we see it constituted and as the first success story of our vehicle.”
The peripheral nerves allow us to perform all daily activities, such as walking, running, catching, hugging or feeling. There are several types of injuries that peripheral nerves can suffer due to trauma, infection, metabolic or inherited problems or exposure to toxins. For example, some injuries can happen after a violent accident, through the section of the nerves of the hand, but also by complications, such as hernias or carpal tunnel syndrome. Common symptoms include tingling, numbness and pain and, in the most severe cases, loss of sensory, motor or autonomic nervous function.
From Left: Dr. David Romeo (Co-founder), Dr. Joaquim Forés (Co-founder), Dra. Caty Casas (Co-founder), Dr. Armand Sánchez (ViceChair of Research and Transference of UAB) and Dr. Josep Lluís Falcó (CEO at GENESIS Ventures).